Deguelin use as supplementary therapy of chronic lymphoid leukemia

Using deguelin as supplementary therapy of chronic lymphoid leukemia. # The present invention relates to the use of deguelin or salts or esters of this compound, as a supplementary therapy to adequate primary therapy for the treatment of chronic lymphoid leukemia . Particularly, the present invention relates to the use of a composition comprising deguelin or pharmaceutically acceptable salts or esters of this compound, for the manufacture of a medicament for use as administered adjunctive therapy simultaneously, alternately or sequentially to a suitable primary therapy for treatment of chronic lymphoid leukemia, wherein said primary therapy comprises fludarabine or pharmaceutically acceptable salts or esters of this compound.